NCT00135200 2025-04-30
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed
Clinical Trials
11 trialsNCT00006695 2023-09-01
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT01484093 2023-08-16
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00777114 2018-08-13
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Weill Medical College of Cornell University
Phase 1 Completed
NCT00476047 2017-10-12
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00073918 2017-08-18
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00577629 2017-05-30
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Duke University
Phase 2 Completed
NCT00490009 2017-03-30
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Stanford University
Phase 2 Completed
NCT00434629 2016-08-17
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
University of Pennsylvania
Phase 1 Completed
NCT00073931 2015-02-05
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00110071 2014-08-06
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Completed